Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Free White Paper

WuXi Reports Improved Quarter, Again

publication date: May 28, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

WuXi PharmaTech Inc. reported Q1 revenues were 69% higher than year-earlier numbers at $57.1 million. However, this year’s revenue includes an $11 million contribution from the AppTec acquisition, which was closed on January 31, 2008. Without AppTec, WuXi’s revenues grew by 36%. Net income jumped 132% to $13.9 million, which works out to an earnings per ADS figure of 19 cents. WuXi reiterated its guidance of 2008 revenues in a $280 million-$300 million range. More details...

Stock Symbol: (NYSE: WX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Other Events

China Pharmaceutical R&D Summit
April 23-26, 2012
Shanghai, China


Biosimilars Asia 2012
April 23-26, 2012
Shanghai, China


Vaccines China 2012
April 23-26, 2012
Shanghai, China

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners